StreetAlpha.app
Home › Stocks › OLMA

Olema Oncology, Inc. (OLMA)

Healthcare
$7.22
▼ −1.90%
LAST CLOSE · NOV 17

Olema Pharmaceuticals develops experimental oral drugs for breast cancer, based in San Francisco. It last closed at $7.22 on Nov 17, down 1.90% on the day.

AI Auto Pilots
Is OLMA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$235.9M
EPS (diluted)
−$2.40
Valuation
Market cap
$632.5M
87.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.5M
At Sep 30
Shareholder equity
$368.8M
Shares outstanding
87.6M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$71.1M−$71.1MFY2021FY2022: −$104.8M−$104.8MFY2022FY2023: −$96.7M−$96.7MFY2023FY2024: −$129.5M−$129.5MFY2024FY2025: −$162.5M−$162.5MFY2025

From OLMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated OLMA in the past 90 days, not enough for a consensus
Average 12-month target
$30.00
▲ 315.5% upside

Based on 1 analyst who set a price target on OLMA in the past 90 days. The average target is $30.00, with a high of $30.00 and a low of $30.00, compared with the last close of $7.22.

Low $30.00Avg $30.00High $30.00
Blue marker: last close $7.22
Highest target$30.00
Average target$30.00
Lowest target$30.00
Latest rating changes
StifelMaintained
Sep 14Buy$30
JP MorganMaintained
Aug 13Buy$46
CitigroupMaintained
Aug 11Buy$59
HC Wainwright & Co.Maintained
Aug 11Buy$36
DateFirmActionRatingPrice target
Sep 14StifelMaintainedBuy$30
Aug 13JP MorganMaintainedBuy$46
Aug 11CitigroupMaintainedBuy$59
Aug 11HC Wainwright & Co.MaintainedBuy$36
Loading…

Technical Analysis

OLMA · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 79% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the Pivot at $7.20, and the nearest resistance the Pivot R1 at $7.38.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.7%/day
Key levels
$36.2652 week high+402.2%
$12.90200 day average+78.7%
$9.72100 day average+34.6%
$8.0450 day average+11.4%
$7.60Swing high (Oct 29)+5.3%
$7.38Pivot R1+2.2%
$7.2220 day average+0.0%
$7.22Last close
$7.20Pivot−0.3%
$7.04Pivot S1−2.5%
$6.71Swing low (Nov 5)−7.1%
$6.2452 week low−13.6%
Indicators
RSI (14)46.06Middle of its rangeNeutral
MACD-0.12Above its signal lineBullish
Stochastic45.4Middle of its rangeNeutral
ADX (14)20.8Weak trend
Williams %R-66.9Oversold below −80, overbought above −20Neutral
CCI (20)0.6Oversold below −100, overbought above 100Neutral
Rate of change−1.8%Change over 10 sessionsBearish
ATR (14)$0.55Typical daily range, 7.7% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for OLMA

What happened before

See how OLMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OLMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OLMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OLMA in the last 90 days.

Loading…

See today’s whale options flow across the market →

OLMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲97 buying vs 76 selling
  • ●Held by funds +0.3 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding180185−2.7%
In funds' top 10220.0%
Held by funds116.6%116.3%+0.3 pts
New / increased26 / 7123 / 740.0%
Reduced / sold out45 / 3160 / 35−20.0%
Put/call ratio0.020.11−85.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OLMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OLMA is in one of them and how their past OLMA trades turned out.

OLMA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OLMA in an article yet. Here's the latest on the wider market.

About Olema Oncology

Olema Pharmaceuticals is a drug developer based in San Francisco, California. It is developing oral medicines for breast cancer, led by palazestrant, an experimental drug that blocks the estrogen receptor and breaks it down. The company is also developing OP3136, a treatment that targets the KAT6 protein. If approved, these drugs would be prescribed to women with breast cancer. None of its products are approved for sale yet, so it has no product sales.

Headquarters
South San Francisco, CA